TY  - GEN
AU  - Gebhart,G
AU  - Lamberts,L E
AU  - Wimana,Z
AU  - Garcia,C
AU  - Emonts,P
AU  - Ameye,L
AU  - Stroobants,S
AU  - Huizing,M
AU  - Aftimos,P
AU  - Tol,J
AU  - Oyen,W J G
AU  - Vugts,D J
AU  - Hoekstra,O S
AU  - Schröder,C P
AU  - Menke-van der Houven van Oordt,C W
AU  - Guiot,T
AU  - Brouwers,A H
AU  - Awada,A
AU  - de Vries,E G E
AU  - Flamen,P
TI  - Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
SN  - 1569-8041
PY  - 2016///1213
KW  - Ado-Trastuzumab Emtansine
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Breast Neoplasms
KW  - diagnostic imaging
KW  - Female
KW  - Fluorodeoxyglucose F18
KW  - Humans
KW  - In Situ Hybridization, Fluorescence
KW  - Maytansine
KW  - Middle Aged
KW  - Positron-Emission Tomography
KW  - Receptor, ErbB-2
KW  - genetics
KW  - Trastuzumab
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1093/annonc/mdv577
ER  -